JP2022531898A - 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸 - Google Patents

転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸 Download PDF

Info

Publication number
JP2022531898A
JP2022531898A JP2021566160A JP2021566160A JP2022531898A JP 2022531898 A JP2022531898 A JP 2022531898A JP 2021566160 A JP2021566160 A JP 2021566160A JP 2021566160 A JP2021566160 A JP 2021566160A JP 2022531898 A JP2022531898 A JP 2022531898A
Authority
JP
Japan
Prior art keywords
patients
compound
dose
patient
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021566160A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020225375A5 (https=
JP2022531898A5 (https=
Inventor
サンドリーヌ・アンハイム－ヘルベリン
シルヴェーヌ・カルト－コットン
マリーナ・セラノヴィック
パトリック・コーエン
アリス・ゴスラン
ゴーチェ・ポー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2022531898A publication Critical patent/JP2022531898A/ja
Publication of JPWO2020225375A5 publication Critical patent/JPWO2020225375A5/ja
Publication of JP2022531898A5 publication Critical patent/JP2022531898A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021566160A 2019-05-09 2020-05-07 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸 Ceased JP2022531898A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19305593 2019-05-09
EP19305593.6 2019-05-09
EP19305679.3 2019-05-28
EP19305679 2019-05-28
US201962945311P 2019-12-09 2019-12-09
US62/945,311 2019-12-09
PCT/EP2020/062743 WO2020225375A1 (en) 2019-05-09 2020-05-07 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients

Publications (3)

Publication Number Publication Date
JP2022531898A true JP2022531898A (ja) 2022-07-12
JPWO2020225375A5 JPWO2020225375A5 (https=) 2023-05-01
JP2022531898A5 JP2022531898A5 (https=) 2023-05-01

Family

ID=70681807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566160A Ceased JP2022531898A (ja) 2019-05-09 2020-05-07 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸

Country Status (13)

Country Link
US (2) US20200352905A1 (https=)
EP (1) EP3965758A1 (https=)
JP (1) JP2022531898A (https=)
KR (1) KR20220006553A (https=)
CN (1) CN114173776A (https=)
AU (1) AU2020268762A1 (https=)
BR (1) BR112021022216A2 (https=)
CA (1) CA3146346A1 (https=)
IL (1) IL287805A (https=)
MX (1) MX2021013711A (https=)
SG (1) SG11202111979SA (https=)
TW (1) TW202110434A (https=)
WO (1) WO2020225375A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7413363B2 (ja) 2018-09-07 2024-01-15 サノフイ メチル６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボキシレートの調製方法
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
KR20220113695A (ko) 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
EP4247363A1 (en) * 2020-11-23 2023-09-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TW202400136A (zh) * 2022-03-13 2024-01-01 法商賽諾菲公司 以安森司群(amcenestrant)治療乳癌
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520388A (ja) * 1998-07-18 2002-07-09 シエーリング アクチエンゲゼルシヤフト ベンゾシクロヘプテン、これらの製造方法、これらの化合物を含有する医薬品調剤ならびに薬剤の製造のためのその使用
JP2018518529A (ja) * 2015-04-29 2018-07-12 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
JP2018537406A (ja) * 2016-02-15 2018-12-20 サノフイＳａｎｏｆｉ エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体
JP2019502675A (ja) * 2015-12-09 2019-01-31 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ ベンゾチオフェン系選択的エストロゲン受容体ダウンレギュレーター
WO2019020559A1 (en) * 2017-07-24 2019-01-31 Sanofi COMBINATION COMPRISING PALBOCICLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] OXYPHENYL] -8,9-DIHYDRO ACID -7H-BENZO [7] ANNULENE-2-CARBOXYLIC AND ITS USE FOR THE TREATMENT OF CANCER

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082990A1 (en) * 2013-12-06 2015-06-11 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520388A (ja) * 1998-07-18 2002-07-09 シエーリング アクチエンゲゼルシヤフト ベンゾシクロヘプテン、これらの製造方法、これらの化合物を含有する医薬品調剤ならびに薬剤の製造のためのその使用
JP2018518529A (ja) * 2015-04-29 2018-07-12 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
JP2019502675A (ja) * 2015-12-09 2019-01-31 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ ベンゾチオフェン系選択的エストロゲン受容体ダウンレギュレーター
JP2018537406A (ja) * 2016-02-15 2018-12-20 サノフイＳａｎｏｆｉ エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体
WO2019020559A1 (en) * 2017-07-24 2019-01-31 Sanofi COMBINATION COMPRISING PALBOCICLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] OXYPHENYL] -8,9-DIHYDRO ACID -7H-BENZO [7] ANNULENE-2-CARBOXYLIC AND ITS USE FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
KR20220006553A (ko) 2022-01-17
IL287805A (en) 2022-01-01
US20200352905A1 (en) 2020-11-12
EP3965758A1 (en) 2022-03-16
AU2020268762A1 (en) 2021-12-02
WO2020225375A1 (en) 2020-11-12
MX2021013711A (es) 2021-12-10
CA3146346A1 (en) 2020-11-12
TW202110434A (zh) 2021-03-16
US20240091194A1 (en) 2024-03-21
SG11202111979SA (en) 2021-11-29
BR112021022216A2 (pt) 2021-12-28
CN114173776A (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
JP2022531898A (ja) 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸
KR20200014298A (ko) Her2 양성 암의 치료
AU2019350581B2 (en) Methods of treatment of cancer comprising Cdc7 inhibitors
US20250127759A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
CN115867669A (zh) 监测kras突变的方法
JP2024510612A (ja) ソトラシブ投与レジメン
CN120267673A (zh) 用于治疗癌症的剂量方案
CA3140146A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
US20250186393A1 (en) Treatment of breast cancer with amcenestrant
TWI918645B (zh) 用於治療癌症之劑量方案
US20260116962A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
US20250177414A1 (en) Combination therapies for treatment of breast cancer
KR20260006644A (ko) 유방암 치료에 사용하기 위한 카피바서티브, cdk4/6 억제제 및 풀베스트란트의 조합
CN118804747A (zh) 用安森司群治疗乳腺癌
WO2025202971A1 (en) Kras g12c inhibitor for use for the treatment of non-small cell lung cancer
JP2023086719A (ja) Ｃｄｋ４及び６阻害剤で以前に治療された患者におけるホルモン受容体陽性でヒト上皮成長因子受容体２陰性の進行性又は転移性乳がんの治療のためのフルベストラントとのｃｄｋ４及び６阻害剤の併用
EA048255B1 (ru) Режим дозирования для лечения рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240702

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241129

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250325